GBA Presents: House of Gummy-!

9188a1ff363e82a30af4be5d925bf80e

Bill Gates speaks of visiting Churchill Downs
 
stonedinvestor said:
DICE scored GBA a 2nd round of gains-! Try that home kids. I alwayd said DICE would be bought and it was- This Co also has that feel.
Drug Stock Poised For Growth With Record Sales, Strong Outlook

Licensing

  • 02:13 PM ET 06/20/2023
Intra-Cellular Therapies (ITCI) is finding support at the 21-day moving average in a flat base. The buy point is 66.56. The growth stock is in the IBD 50 list of stocks with strong fundamental and technical ratings and matching price performance.

The early-stage base-on-base pattern has a depth of 12%, according to IBD MarketSmith chart analysis.

The growth stock has a stellar record of sales increases over the past seven quarters. Sales have grown at a compounded rate of 55% over the past 10 years and ranged from 120% to a staggering 950% from previous year quarters.

Sales of $95.3 million grew an impressive 172% in the fiscal first quarter, though the loss per share of 46 cents shows that the company has yet to become profitable. Its drug Caplyta accounted for almost all sales, with total prescriptions increasing 159%. ITCI stock rose after results and broke out on May 1 as part of a five day-winning streak before starting the new base.

Analysts polled by FactSet expect a steeper loss of 60 cents per share for the June quarter on sales of $106 million.

For fiscal 2023, the company expects sales of Caplyta to be around $430 million to $455 million.

Growth Stock Surges On Positive Results for Lumateperone
Intra-Cellular shares surged on March 28 after the New York company announced positive results at week 6 for it double-blinded placebo-controlled randomized study of its drug Lumateperone to treat depressive and bipolar disorders with mixed features. Mixed features — which include depressive symptoms during a manic phase and vice versa — have been the more difficult to treat.

For high-growth companies, cash position is a key data point to watch. ITCI ended with $541 million in cash for the first quarter, compared with $594 million a year ago.

ITCI stock has an adequate Composite Rating of 89 and an RS Rating of 90. The stock has gained 22% so far this year. It trades at a price-to-sales ratio of 19.6, according to FactSet. It is in the highly ranked medical biomedical group, which sits at No. 21 in IBD's 197 industry groups.

Intra-Cellular specializes in small molecule drug treatments for neurological diseases, such as Alzheimer's, by targeting intracellular signals in the central nervous system.

Its chief drug, Caplyta, is approved for treating schizophrenia and conditions associated with bipolar disorder in adults. The drug is used as a primary treatment or in combination with lithium or FDA-approved drugs to treat mixed-features disorders.
More...
I just looked.
You do realize this thing was at $46 all day.
Kinda outta character for you Stoney if you owned it.
Shouldn't we have heard about it like at 7AM? And then the rest of the day?:rolleyes:
Loyal readers got stopped out long ago. :mad:

I should cut and paste my Ferrari posts. If that gains one savantness. (?)
And the readers weren't stopped out. btw.
Here.... Stocks with staying power:
https://www.elitetrader.com/et/threads/the-stock-that-never-goes-down.311694/
:p
 

China unveils $72 billion tax break for EVs, other green cars to spur demand-:wtf::wtf:
3
d57726d0283f5cab835625829eb2f0bb

A electric car charging station is pictured in a parking lot in Shanghai





BEIJING/SHANGHAI (Reuters) -China unveiled on Wednesday a 520 billion yuan ($72.3 billion) package of tax breaks over four years for electric vehicles (EVs) and other green cars, its biggest yet for the industry as it seeks to boost slower auto sales growth.

Weakening sales growth in the world's biggest auto market has raised concern over China's economic growth and while financial support was widely expected after an earlier government pledge to promote the industry, shares in major automakers jumped after the details were released.

"The extension by another four years beat market expectations," said Cui Dongshu, secretary general of the China Passenger Car Association.

New energy vehicles (NEVs) purchased in 2024 and 2025 will be exempted from purchase tax amounting to as much as 30,000 yuan ($4,170) per vehicle. The exemption will be halved and capped at 15,000 yuan for purchases made in 2026 and 2027, the Ministry of Finance said in a statement.

China had also previously offered a subsidy for EV purchases for more than a decade but the programme ended last year.

Chinese auto shares rallied after the announcement, with EV makers NIO and Xpeng rising 6.1% and 5.5% respectively, versus a 1.9% drop in Hong Kong's benchmark index. Li Auto also surged 3.5%.
 
Loyal readers got stopped out long ago.

lol.> We re entered DICE after pocketing $20 // then we told you to get back in after the selloff

I thought I would save you from a barrage of old posts from the other threada because they tend to re push that thread up when I mistakenly hit quote but I can gladly get you the exact numbers

Loyal readers made off like bandits
 
DICE-

This is a Bio we used earlier in the thread it was a huge 100% gainer for the children.

In the big picture it went from 20 to 40 to 30. Look at 6 months. it's a classic pattern.

A rule of thumb is you take the amount of the big move divide by two and that's your entry point.

Now I must admit I have lost track of DICE and it's prospects. Biotech has it's times and its not times and it's just not a good time for Bio now.- So I'm not actively looking in that area.

However-- DICE has my attention again.

#12958 Jan 26, 2023 Report
Reply Share
 
Wow this is really tempting. A company we owned and i still like.

Dice Therapeutics discloses $14.8M purchase of common stock by Ra Capital 18:23 DICE

I am being lured in here... I want so much./ I give lectures to Van about recognizing feelings inside one's self that mean the opposite of whatever is happening...

This feeling of want of more of transferring money of buying fucking DICE tomorrow...

Does it mean we are right at a top.

#16000 Mar 31, 2023 Report
Reply Share
 
Back in just under $35 // should of been $29 as you can see///

Can't say I did not hold your hand through the whole process.


A-DICE Therapeutics, Inc. (DICE)
NasdaqGM - NasdaqGM Real Time Price.
34.77+2.11 (+6.46%)
As of 12:06PM EDT.

Would of should of bought this at $30. Don't really want another Bio at this point! But this one is best placed>>>
I have OCUL and MCRB and ZYME

#484 May 22, 2023 Report
Reply Share
 
You must log in or register to reply here.
Back
Top